Reusable lancing device market seen reaching $23.25B by 2030

The reusable lancing device market is projected to grow from $14.43 billion in 2025 to $15.85 billion in 2026, as diabetes monitoring demand rises worldwide. The Business Research Company says the market could reach $23.25 billion by 2030, led by home healthcare use, safety features and faster growth in Asia-Pacific.

Why it matters: - Reusable lancing devices are tied to diabetes care, where frequent blood glucose testing is routine. - Rising diabetes prevalence is increasing demand for patient-friendly and lower-cost sampling tools. - The market’s growth reflects broader pressure on healthcare systems to support home monitoring and preventive screening.

What happened: - The Business Research Company published its Reusable Lancing Device Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report puts the reusable lancing device market at $14.43 billion in 2025 and $15.85 billion in 2026. - The report forecasts the market will reach $23.25 billion by 2030. - The report was distributed from London on Sept. 22, 2026. - A free sample is available here. - The full report is available here.

The details: - The market is expected to grow at a 9.8% CAGR in 2026. - The report forecasts a 10.1% CAGR through 2030. - Growth drivers in the historical period include rising diabetes cases, higher awareness of regular blood glucose monitoring, more hospital and diagnostic testing, safer lancet and device designs, and wider access to diabetes management programs. - Future growth is expected to come from home healthcare monitoring, patient-centric blood sampling devices, preventive screening programs, higher healthcare spending in emerging markets, and more ergonomic reusable devices. - Expected product trends include safety-engineered devices to reduce needlestick injuries, adjustable depth settings for personalized sampling, reusable formats to lower long-term costs, expanded home glucose monitoring, and lower-pain technologies. - Reusable lancing devices are handheld tools that collect capillary blood samples by pricking the skin. - The devices use replaceable sterile lancets and usually offer adjustable penetration depth. - The design is intended to make blood sampling safer, more comfortable and more cost-effective. - The International Diabetes Federation reported in April 2024 that the global adult diabetic population reached 589 million in 2024. - The International Diabetes Federation projects that number will rise to 853 million by 2050. - North America held the largest regional share in 2025. - Asia-Pacific is expected to be the fastest-growing region. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast points to a market shaped by two forces at once: more diabetes diagnoses and more care shifting outside hospitals. - Product competition appears to be moving toward comfort, safety and customization rather than basic functionality alone. - The regional split suggests mature demand in North America and faster expansion where healthcare infrastructure is still scaling. - The company’s emphasis on dashboards, scoring tools and hotspots signals that buyers want more than a static market snapshot.

What's next: - Growth will likely track diabetes prevalence, adoption of home monitoring and investment in healthcare infrastructure. - Device makers are expected to push further into low-pain and safety-engineered designs. - Asia-Pacific may capture a growing share if medical access and screening expand as forecast. - The Business Research Company said the 2026 report set includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards and trend graphics.

The bottom line: - Reusable lancing devices are moving from a niche diabetes accessory to a broader, globally expanding monitoring category.